Allogene Therapeutics ALLO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32M-36.2% | $28.63M-36.3% | $31.16M-30.3% | $40.16M-20.3% | $50.2M-3.9% | ||
| $14.09M-6.0% | $13.77M-11.3% | $13.74M-15.9% | $14.28M-11.2% | $14.99M-13.2% | ||
| $46.09M-29.3% | $42.4M-29.9% | $44.9M-37.4% | $56.82M-20.5% | $65.19M-6.2% | ||
| -$46.09M+29.3% | -$42.4M+29.9% | -$44.9M+37.4% | -$56.82M+20.5% | -$65.19M+6.2% | ||
| $300K+100% | $313K+286% | $344K+244% | $268K— | $150K— | ||
| $3.49M-36.1% | $3.59M+262% | $3.5M-36.1% | $5.88M+15.8% | $5.46M+21.2% | ||
| -$42.61M+28.7% | -$38.81M+35.3% | -$41.4M+37.5% | -$50.94M+23.2% | -$59.73M+8.1% | ||
| -$0.18+35.7% | -$0.17+39.3% | -$0.19+40.6% | -$0.23+34.3% | -$0.28+26.3% | ||
| -$43.22M+30.4% | -$39.35M+31.3% | -$41.8M+39.0% | -$53.71M+20.8% | -$62.09M+5.8% | ||
| -$46.09M+29.3% | -$42.4M+29.9% | -$44.9M+37.4% | -$56.82M+20.5% | -$65.19M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Allogene Therapeutics profitable?
- Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
- What is Allogene Therapeutics's earnings per share?
- Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
- Where does Allogene Therapeutics's income statement data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.